AZTR

Azitra Inc. (AZTR) | Rumor.io

Azitra

AZTR

Attention (50-day avg)0%

Attention rank (50-day avg)#2,897

Bullish sentiment (50-day avg)96%

Price to earnings ratio8.39

Market capitalization10.3M

Earnings per share0.02

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-11M

Social

What share of all stock conversation is about AZTR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 24

Azitra, Inc. ($AZTR) achieved NYSE compliance, presenting at the HCWainwright conference in September to outline upcoming catalysts.
The company has seen good volume and a nice move in after-hours trading, with some analysts predicting a move up to $0.30 or higher.
Short sellers are heavily invested in Azitra, with one analyst noting that the shorts are "al[l]l" over the stock.

Generated by AI

Sentiment

Of the messages about AZTR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	91.06% +6.5
Bearish	—	—	—	8.94% -6.5

Bullish· Jun 22

Azitra, Inc. (AZTR) has strong momentum in the small-cap biotech space, with shares surging after announcing a securities purchase agreement with a healthcare-focused institutional investor.
AZTR is experiencing a steady, quiet move that could be a sign of a legitimate and sustainable trend, with the potential for a significant increase in value.
The company's business reorientation has contributed to its recent success, and there is a possibility of a 50-100% run in the stock, making it a potentially lucrative opportunity for traders.

Bearish· Jun 22

The asset's price movement is being manipulated, with the company allegedly dumping short shares and buying the ask, creating a large spread.
The company has a history of dilution, with a significant drop in share price from $950 per share three years ago.
The asset's price is being artificially held back, with the spread suggesting that the company is trying to suppress its value.

Generated by AI

Topics

Of the messages about AZTR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	21.97%
Controversies	—	—	0%	0.09%
Technical Analysis	—	—	0%	33.35%
Analysts	—	—	0%	21.54%
Earnings	—	—	0%	0%
Macro	—	—	0%	23.05%

Announcements· Mar 20

Azitra, Inc. (AZTR) announced a $10.5 million private placement to fund protein and peptide research for the cosmetics market.
The company also priced a private placement for up to $31.4 million, including $10.5 million, with warrants exercisable at $0.123 to fund research.
Azitra will use the funding to advance new cosmetic protein and peptide programs, with a focus on innovative research in the cosmetic and dermatology space.

Technical Analysis· Mar 20

The asset is in a bull flag formation, with a potential breakout above .32, and the author took profits at .32-.33, but maintains an original position.
The asset has formed a pennant and consolidated at 0.31, with the author watching for a breakout past .32 with momentum.
The asset has broken out of consolidation, with high volume and a rising RSI, indicating a potential strong upward move.

Generated by AI

Community

Of the messages about AZTR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	31.72%
Newcomers	—	—	0%	68.28%

Regulars· Mar 20

Azitra, Inc. ($AZTR) has seen a significant increase in sub-dollar gaps since 2020, indicating a volatile market.
The company is poised for a breakout, with a potential push of volume needed to follow through on its quick price pops.
Azitra's private placement of $31 million is a significant development, and the company's cancer treatment program at MD Anderson is gaining traction, potentially leading to a stock price increase.

Newcomers· Aug 24

New investors are focusing on the company's recent compliance with the AMEX exchange, citing it as a positive catalyst for the stock.
There is a strong presence of short sellers in the stock, with some users expressing their frustration and concern about the tone of volume at the close.
Some newcomers are interpreting the recent price action as a "pump and dump" scheme, with one user predicting the stock will go below $10.

Generated by AI

News

Azitra at H.C. Wainwright conference: pipeline leans on skin bacteria

18d agoInvesting.com

Azitra Regains NYSE American Listing Compliance Status

Detailed price information for Azitra Inc (AZTR-A) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Azitra regains compliance with NYSE American listing standards

1mo agoInvesting.com

Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards

Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today announced that it has received written notification from NYSE American LLC ("NYSE American") confirming that the Company has regained compliance with all of the NYSE American continued listing standards set forth in Part 10 of the NYSE American Company Guide.

1mo agoYahoo Finance

Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates

Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today reported financial results for the quarter ended June 30, 2026, and provided a business update.

1mo agoYahoo Finance

/C O R R E C T I O N -- Azitra, Inc./

Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today announced promising results from two separate ex vivo human skin tissue studies. The studies evaluated the distribution and anti-wrinkle activity of Azitra's filaggrin domain containing supernatant in two separate experimental studies.

2mo agoYahoo Finance

Also Discussed

Investors talking about AZTR also mention

#	Name	Attention
1	Linkers Industries LimitedLNKS	0%0
2	Agape Atp CorpATPC	0%0
3	UOKA - MDJM Ltd	——
4	VCI Global Ltd.VCIG	0%0
5	60 Degrees Pharmaceuticals Inc.SXTP	0%+0
6	Mangoceuticals, Inc.MGRX	0%0
7	Mira Pharmaceuticals, Inc.MIRA	0%0
8	ASNS - Actelis Networks, Inc.	——
9	CDT Equity Inc.CDT	0%+0
10	Interactive Strength Inc.TRNR	0%0

Azitra Inc.

Healthcare
Biotechnology

Azitra Inc. is a clinical-stage biopharmaceutical company focused on precision dermatology. The company develops topical live biotherapeutic products and engineered protein-based therapeutics designed to address skin diseases by working with the skin microbiome. Its platform combines synthetic biology, microbial engineering, and protein design to create treatments for dermatologic conditions, including rare and hard-to-treat disorders. Azitra Inc. also uses a proprietary microbial library and data-driven screening tools to identify bacterial strains with therapeutic potential. The company’s current product portfolio includes investigational candidates aimed at dermatology and skin-barrier disorders, positioning Azitra Inc. within the specialized market for microbiome-based skin treatments and targeted dermatologic therapeutics.

Website

Location

21 Business Park Drive

Branford, CT, 06405

United States

Social

What share of all stock conversation is about AZTR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 24

Azitra, Inc. ($AZTR) achieved NYSE compliance, presenting at the HCWainwright conference in September to outline upcoming catalysts.
The company has seen good volume and a nice move in after-hours trading, with some analysts predicting a move up to $0.30 or higher.
Short sellers are heavily invested in Azitra, with one analyst noting that the shorts are "al[l]l" over the stock.

Generated by AI

Sentiment

Of the messages about AZTR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	91.06% +6.5
Bearish	—	—	—	8.94% -6.5

Bullish· Jun 22

Azitra, Inc. (AZTR) has strong momentum in the small-cap biotech space, with shares surging after announcing a securities purchase agreement with a healthcare-focused institutional investor.
AZTR is experiencing a steady, quiet move that could be a sign of a legitimate and sustainable trend, with the potential for a significant increase in value.
The company's business reorientation has contributed to its recent success, and there is a possibility of a 50-100% run in the stock, making it a potentially lucrative opportunity for traders.

Bearish· Jun 22

The asset's price movement is being manipulated, with the company allegedly dumping short shares and buying the ask, creating a large spread.
The company has a history of dilution, with a significant drop in share price from $950 per share three years ago.
The asset's price is being artificially held back, with the spread suggesting that the company is trying to suppress its value.

Generated by AI

Topics

Of the messages about AZTR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	21.97%
Controversies	—	—	0%	0.09%
Technical Analysis	—	—	0%	33.35%
Analysts	—	—	0%	21.54%
Earnings	—	—	0%	0%
Macro	—	—	0%	23.05%

Announcements· Mar 20

Azitra, Inc. (AZTR) announced a $10.5 million private placement to fund protein and peptide research for the cosmetics market.
The company also priced a private placement for up to $31.4 million, including $10.5 million, with warrants exercisable at $0.123 to fund research.
Azitra will use the funding to advance new cosmetic protein and peptide programs, with a focus on innovative research in the cosmetic and dermatology space.

Technical Analysis· Mar 20

The asset is in a bull flag formation, with a potential breakout above .32, and the author took profits at .32-.33, but maintains an original position.
The asset has formed a pennant and consolidated at 0.31, with the author watching for a breakout past .32 with momentum.
The asset has broken out of consolidation, with high volume and a rising RSI, indicating a potential strong upward move.

Generated by AI

Community

Of the messages about AZTR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	31.72%
Newcomers	—	—	0%	68.28%

Regulars· Mar 20

Azitra, Inc. ($AZTR) has seen a significant increase in sub-dollar gaps since 2020, indicating a volatile market.
The company is poised for a breakout, with a potential push of volume needed to follow through on its quick price pops.
Azitra's private placement of $31 million is a significant development, and the company's cancer treatment program at MD Anderson is gaining traction, potentially leading to a stock price increase.

Newcomers· Aug 24

New investors are focusing on the company's recent compliance with the AMEX exchange, citing it as a positive catalyst for the stock.
There is a strong presence of short sellers in the stock, with some users expressing their frustration and concern about the tone of volume at the close.
Some newcomers are interpreting the recent price action as a "pump and dump" scheme, with one user predicting the stock will go below $10.

Generated by AI

Azitra

Social

Aug 24

Bullish· Jun 22

Bearish· Jun 22

Announcements· Mar 20

Technical Analysis· Mar 20

Regulars· Mar 20

Newcomers· Aug 24

Azitra at H.C. Wainwright conference: pipeline leans on skin bacteria

Azitra Regains NYSE American Listing Compliance Status

Azitra regains compliance with NYSE American listing standards

Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards

Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates

/C O R R E C T I O N -- Azitra, Inc./

Also Discussed

Azitra Inc.

Company Information

Location

Azitra at H.C. Wainwright conference: pipeline leans on skin bacteria

Azitra Regains NYSE American Listing Compliance Status

Azitra regains compliance with NYSE American listing standards

Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards

Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates

/C O R R E C T I O N -- Azitra, Inc./

Also Discussed

Social

Aug 24

Bullish· Jun 22

Bearish· Jun 22

Announcements· Mar 20

Technical Analysis· Mar 20

Regulars· Mar 20

Newcomers· Aug 24